Ardelyx, Inc. (ARDX) vs Lexicon Pharmaceuticals, Inc. (LXRX)

Ardelyx, Inc. and Lexicon Pharmaceuticals, Inc. are both Biotechnology companies. Ardelyx, Inc. and Lexicon Pharmaceuticals, Inc. are of similar size ($859.7M and $854.3M). Ardelyx, Inc. grew revenue faster over the last twelve months: 16.8% against −29.0%. Ardelyx, Inc. has the higher net margin (−12.4% vs −147.4%) and the higher return on invested capital (−18.6% vs −96.4%). Across the 18 metrics below, Ardelyx, Inc. leads on 12 and Lexicon Pharmaceuticals, Inc. on 6.

Valuation

Metric ARDX LXRX Biotechnology median
P/E n/m n/m 7.88
P/S 1.88 19.00 11.47
P/B 5.69 4.51 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 1.82 15.75 10.73
Earnings yield (6.55%) (8.48%) (28.84%)
Free cash flow yield (2.11%) (8.38%) (23.03%)

Profitability

Metric ARDX LXRX Biotechnology median
Gross margin 94.37% 99.14% 65.16%
Operating margin (7.86%) (131.43%) 0.00%
Net margin (12.35%) (147.38%) 0.00%
Free cash flow margin (3.97%) (156.71%) 0.00%
Return on equity (38.61%) (40.21%) (57.72%)
Return on assets (10.68%) (25.70%) (49.22%)
Return on invested capital (18.62%) (96.36%) 0.00%

Growth

Metric ARDX LXRX Biotechnology median
Revenue growth (TTM) 16.77% (29.03%) 5.64%
EPS growth (last fiscal year) (52.94%) 77.78% —
Revenue growth, 5-year CAGR 121.90% 15.72% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ARDX LXRX Biotechnology median
Debt to equity 1.69 0.29 0.00
Current ratio 3.34 13.37 4.73
Net debt to EBITDA 1.63 0.91 0.96

Dividend

Metric ARDX LXRX Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric ARDX LXRX Biotechnology median
Market cap 859.70m 854.32m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack